Status:

COMPLETED

Clinical Trial in Patients With Metastatic Colorectal Cancer

Lead Sponsor:

Mast Therapeutics, Inc.

Collaborating Sponsors:

University of California, San Diego

Conditions:

Colon Cancer

Rectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the ad...

Eligibility Criteria

Inclusion

  • Patients must have surgically incurable colon or rectal adenocarcinoma
  • Karnofsky Performance Status of 60% or greater
  • Patients may have symptomatic neuropathy
  • Patients must have a life expectancy of at least 4 months
  • Patients must be alimenting, receiving at least 1500Kcal/day nutrition, by any route
  • Patients must have bidimensional measurable disease for response assessment
  • Patients may have received adjuvant chemotherapy with fluoropyrimidine therapy
  • Patients must have recovered from the toxicities of prior therapy, at least 4 weeks since prior adjuvant chemotherapy and major surgery
  • Serum creatinine less than 2.4mg%, serum bilirubin less than 3.0mg%, WBC greater than 3,200/mm2, AGC greater than 1,500/mm3, platelet count greater than 90,000/mm3 and SGOT (AST) and SGPT (ALT) less than 3 times the upper limit of normal
  • Male and non-pregnant, non-lactating female patients must be \>18 years old.

Exclusion

  • Concurrent infection
  • Failure of the patient or the patient's legal representative to sign the Informed consent
  • Inability to obtain Informed Consent because of psychiatric or complex medical problem
  • Patients with unstable oncologic emergency
  • Patients with unstable medical conditions such as angina, transient ischemic attacks, rising creatinine, accelerated hypertension, etc.
  • Cerebellar neurologic syndromes such as Parkinson's Disease, multiple sclerosis and amyotonia
  • Known intolerance to fluoropyrimidine therapy suggestive of dihydropyrimidine dehydrogenase deficiency.

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

End Date :

January 1 2007

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT00081627

Start Date

April 1 2004

End Date

January 1 2007

Last Update

November 27 2007

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

UCSD Moores Cancer Center

La Jolla, California, United States, 92037

2

Mercy General Hospital

Sacramento, California, United States, 95819

3

VA San Diego Healthcare System

San Diego, California, United States, 92161

4

Spectrum Health

Grand Rapids, Michigan, United States, 49503